Founded in 1994, Genesis is a biotechnology company based in Auckland, New Zealand, with a history of development of therapeutics for the treatment of cancer and diseases of the immune system.
Genesis has established Solirna Biosciences Ltd to develop a novel single stranded gene silencing technology which acts through the RNAi mechanism.
Genesis is listed on the New Zealand and Australian Stock Exchanges (GEN).
